vs
Side-by-side financial comparison of Celularity Inc (CELU) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $5.3M, roughly 1.2× Celularity Inc). Prelude Therapeutics Inc runs the higher net margin — -303.5% vs -436.7%, a 133.3% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs -43.2%).
Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.
CELU vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $6.5M |
| Net Profit | $-23.1M | $-19.7M |
| Gross Margin | 26.1% | — |
| Operating Margin | -244.1% | -314.1% |
| Net Margin | -436.7% | -303.5% |
| Revenue YoY | -43.2% | 116.7% |
| Net Profit YoY | -43.3% | 38.9% |
| EPS (diluted) | $-0.88 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $5.3M | $6.5M | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $9.3M | $3.0M | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $14.7M | — | ||
| Q4 23 | $12.1M | — |
| Q3 25 | $-23.1M | $-19.7M | ||
| Q2 25 | $-24.5M | — | ||
| Q1 25 | $-19.8M | — | ||
| Q4 24 | $-13.3M | — | ||
| Q3 24 | $-16.1M | $-32.3M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $-22.0M | — | ||
| Q4 23 | $9.5M | — |
| Q3 25 | 26.1% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | 68.9% | — | ||
| Q4 24 | 59.5% | — | ||
| Q3 24 | 58.2% | — | ||
| Q2 24 | 82.5% | — | ||
| Q1 24 | 88.8% | — | ||
| Q4 23 | 20.7% | — |
| Q3 25 | -244.1% | -314.1% | ||
| Q2 25 | -276.6% | — | ||
| Q1 25 | -91.8% | — | ||
| Q4 24 | -51.2% | — | ||
| Q3 24 | -124.0% | -1145.9% | ||
| Q2 24 | -84.0% | — | ||
| Q1 24 | -50.2% | — | ||
| Q4 23 | — | — |
| Q3 25 | -436.7% | -303.5% | ||
| Q2 25 | -427.5% | — | ||
| Q1 25 | -172.9% | — | ||
| Q4 24 | -73.3% | — | ||
| Q3 24 | -173.2% | -1075.7% | ||
| Q2 24 | -53.6% | — | ||
| Q1 24 | -149.9% | — | ||
| Q4 23 | 78.8% | — |
| Q3 25 | $-0.88 | $-0.26 | ||
| Q2 25 | $-1.02 | — | ||
| Q1 25 | $-0.84 | — | ||
| Q4 24 | $-0.58 | — | ||
| Q3 24 | $-0.73 | $-0.43 | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-1.03 | — | ||
| Q4 23 | $0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0K | $55.0M |
| Total DebtLower is stronger | $35.7M | — |
| Stockholders' EquityBook value | $-20.1M | $58.5M |
| Total Assets | $114.2M | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $120.0K | $55.0M | ||
| Q2 25 | $863.0K | — | ||
| Q1 25 | $293.0K | — | ||
| Q4 24 | $738.0K | — | ||
| Q3 24 | $133.0K | $153.6M | ||
| Q2 24 | $467.0K | — | ||
| Q1 24 | $1.9M | — | ||
| Q4 23 | $227.0K | — |
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | $-20.1M | $58.5M | ||
| Q2 25 | $-25.5M | — | ||
| Q1 25 | $-5.5M | — | ||
| Q4 24 | $8.8M | — | ||
| Q3 24 | $17.3M | $156.4M | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $31.2M | — | ||
| Q4 23 | $41.0M | — |
| Q3 25 | $114.2M | $94.8M | ||
| Q2 25 | $120.3M | — | ||
| Q1 25 | $128.9M | — | ||
| Q4 24 | $132.7M | — | ||
| Q3 24 | $128.8M | $197.2M | ||
| Q2 24 | $135.5M | — | ||
| Q1 24 | $143.8M | — | ||
| Q4 23 | $143.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.2M | $-19.1M | ||
| Q2 25 | $-999.0K | — | ||
| Q1 25 | $-3.0M | — | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-144.0K | $-27.3M | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-4.4M | — | ||
| Q4 23 | $-4.3M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-4.4M | — | ||
| Q4 23 | $-4.9M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | — | -912.0% | ||
| Q2 24 | -28.7% | — | ||
| Q1 24 | -30.3% | — | ||
| Q4 23 | -40.6% | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 4.8% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -0.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
PRLD
Segment breakdown not available.
